Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 7.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie Inc., Astellas, Bayer, Ferring Pharmaceuticals Inc., Genomic Health, Inc., Medivation, Inc., Novartis Pharmaceuticals Corporation, and Sanofi US.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies

New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies


PER Pulse™ Recap

Resources

Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress®
Earn up to 1.5 AMA PRA Category 1 Credits™
Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies consists of a series of interactive clinical vignettes, short video interviews of leading experts in the management of prostate cancer, renal cell carcinoma, and bladder cancer. The activity also features short evidence-based summaries directly related to the treatment of these malignancies. The video interviews address key issues and clinical cases presented and discussed at New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

PER Pulse™ Recap
PER Pulse™ Recaps for Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of expert perspectives on case management decisions is provided in these summaries.



PER Pulse™ Recap

PER Pulse™ Recap
 


1 of 3
PER Pulse™ Recap
Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignanciesis a series of short video interviews with faculty from the live meeting who address a variety of questions commonly faced by practicing urologists and oncologists via discussion of clinical vignettes that were presented at the congress. The activity features discussion on:
  • Immunotherapy for urothelial bladder cancer, by Daniel Petrylak, MD
  • Screening and molecular markers for early prostate cancer (PC), by Leonard Gomella, MD
  • Chemotherapy for advanced, castration-resistant PC (CRPC), by Daniel Petrylak, MD
  • Management of CRPC with bone metastasis, by A. Oliver Sartor, MD
  • Metastatic renal cell carcinoma (RCC), by Toni Choueiri, MD
  • Immunotherapy for RCC, by Mario Sznol, MD

Throughout the activity, these physicians answer questions about their decisions for managing patient cases, and offer perspectives and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Gomella’s answers to questions about the use of screening and molecular markers in PC. During his interview, Dr. Gomella:

  • Reviews controversy around screening for early PC and relevant data. He comments that the controversy over PC screening persists in spite of clear evidence that PC mortality has declined over the past 20 years since prostate-specific antigen (PSA) screening was introduced.
  • Summarizes key takeaways regarding the use of molecular markers in early PC. Advanced molecular markers, including genomics, are now being used in the management of PC, with 4 genomic markers available for use at various points in case management.
  • Summarizes basic practice recommendations for localized PC, and offers his perspective on discussing standard approaches (ie, active surveillance vs local therapy [radiation therapy or radical prostatectomy]) with patients. Focal therapies (eg, high-intensity ultrasound, cryotherapy) receive attention, but are not considered standard therapies at this time.
  • Discusses the significance of family history for patients diagnosed with PC. Family history has an impact on risk of developing PC, but the genetics involved remain unknown. He suggests that young men may want to visit a genetic counselor to assess their risk for PC and other cancers in their families. 

2 of 3
PER Pulse™ Recap
Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignanciesis a series of short video interviews with faculty from the live meeting who address a variety of questions commonly faced by practicing urologists and oncologists via discussion of clinical vignettes that were presented at the congress. The activity features discussion on:

  • Immunotherapy for urothelial bladder cancer by Daniel Petrylak, MD
  • Screening and molecular markers for early prostate cancer (PC) by Leonard Gomella, MD
  • Chemotherapy for advanced, castration-resistant PC (CRPC) by Daniel Petrylak, MD
  • Management of CRPC with bone metastasis by A. Oliver Sartor, MD
  • Metastatic renal cell carcinoma (RCC) by Toni Choueiri, MD
  • Immunotherapy for RCC by Mario Sznol, MD

Throughout the activity, these physicians answer questions about their decisions for managing patient cases, and offer perspectives and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Petrylak’s answers to questions about immunotherapy and emerging strategies for metastatic bladder cancer. During his interview, Dr. Petrylak:

  • Comments on clinical unmet needs in metastatic bladder cancer. While chemotherapy can induce complete response for some patients, the median overall survival for patients treated with chemotherapy has remained at about 15%.
  • Reviews clinical trials of checkpoint inhibitors (eg, nivolumab, pembrolizumab, and atezolizumab).
  • Discusses trials that aim to move novel immune combinations up front, for example, a 3-arm randomized phase III trial of frontline therapy with the anti PD-L1 antibody durvalumab +/- the anti-CTLA-4 antibody tremelimumab versus standard chemotherapy for metastatic bladder cancer (NCT02516241).
  • Shares other areas of research he considers exciting, including trials of maintenance therapy after response to first-line chemotherapy; randomized trials of the antiangiogenic agents bevacizumab and ramucirumab; and investigations of other targeted agents.

3 of 3
PER Pulse™ Recap

Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignanciesis a series of short video interviews with faculty from the live meeting who address a variety of questions commonly faced by practicing urologists and oncologists via discussion of clinical vignettes that were presented at the congress. The activity features discussion on:

  • Immunotherapy for urothelial bladder cancer, by Daniel Petrylak, MD
  • Screening and molecular markers for early prostate cancer (PC), by Leonard Gomella, MD
  • Chemotherapy for advanced, castration-resistant PC (CRPC), by Daniel Petrylak, MD
  • Management of CRPC with bone metastasis, by A. Oliver Sartor, MD
  • Metastatic renal cell carcinoma (RCC), by Toni Choueiri, MD
  • Immunotherapy for RCC, by Mario Sznol, MD

See more at: Community Practice Connections™: New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress®

Throughout the activity, these physicians answer questions about their decisions for managing patient cases, and offer perspectives and guidance on issues important to community-based physicians.

This third of 3 PER Pulse™ Recaps, summarizing the program, focuses on Dr. Sartor’s answers to questions about 2 cases of CRPC with bone metastases. During his interview, Dr. Sartor:

  • Explains the clinical practice points he was hoping to illustrate when he selected these cases to present at New York GU™ 2016, outlining issues related to systemic and local therapy
  • Describes his recommended approaches for each case, including the rationales behind his management plans versus alternative approaches
  • Discusses clinical trials he might consider for these patients
  • Comments on his approach toward multidisciplinary coordination of care and communication across the team of clinicians who care for patients with PC
Provides an overview of his presentation at New York GU™ 2016 titled, Novel Therapies: Radiopharmaceuticals for Castration-Resistant Prostate Cancer
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is not approved for AMA PRA Category 1 Credit™.

Supported by an educational grant from AbbVie Inc, Astellas, Bayer, Genomic Health, Inc., Novartis Pharmaceuticals Corporation, and Sanofi US.






Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By